CTOs on the Move

Sangamo

www.sangamo.com

 
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.sangamo.com
  • 7000 Marina Boulevard
    Richmond, CA USA 94005
  • Phone: 628.252.7500

Executives

Name Title Contact Details
Michael Holmes
Senior Vice President and Chief Technology Officer Profile

Similar Companies

Vivacelle Bio

Welcome to Vivacelle Bio Inc.

Comfort Safety Products

Comfort Safety Products is a Lowell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImClone Systems

ImClone Systems is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Imvax

The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.

DynamiCure

DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease. We are driven by science and passionate about advancing patient care, translating pioneering new insights on immuno-normalization into a pipeline of innovative candidates with first-in-class and best-in-class potential. Since our founding in 2019, we have identified and obtained exclusive global rights to several novel targets and are rapidly advancing into the clinic both monoclonal and bispecific therapeutic antibody candidates.